Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency
Information source: Max-Planck-Institute of Psychiatry
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Partial Corticotrope Insufficiency
Intervention: Hydrocortisone (Drug); Placebo (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Max-Planck-Institute of Psychiatry Official(s) and/or principal investigator(s): Günter K. Stalla, Prof. Dr., Study Director, Affiliation: Max-Planck-Institute, Munich
Summary
The purpose of this study is to evaluate the efficacy of hydrocortisone replacement therapy
in patients with partial cortisol deficiency after traumatic brain injury or subarachnoid
hemorrhage on cognitive function.
Clinical Details
Official title: Phase IV Study to Evaluate the Neuropsychological Effects of Hydrocortisone Substitution in Patients With Partial Adrenal Insufficiency After Traumatic Brain Injury or Subarachnoidal Haemorrhage
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Changes in score of alertness test (TAP)- interindividual differences
Secondary outcome: Changes in score of Alertness Test (TAP) - intraindividual differences
Detailed description:
This is a controlled, randomized, double-blind, placebo-controlled, crossover,
interventional study. The benefit of replacement in partial corticotropic failure on brain
function (cognition), especially in cases with borderline low cortisol levels after
stimulation is unknown.
Moreover, since glucocorticoids might affect hGH secretion, the effect of hydrocortisone on
hGH secretion reflected by IGF-1 levels will be assessed. If IGF-1 is below 2 SD at the end
of the study, hGH secretion will additionally be determined by a GHRH-arginine-test.
An improved cognition in TBI and SAH patients with partial corticotropic insufficiency would
give a new treatment option in this population which may lead to better quality of life and
an enhanced rehabilitation process.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patients (male and female) between 18 and 75 years
- 1 -12 month after TBI or SAH before prescreening
- Cortisol level 100-180 ng/ml after stimulation with ACTH
- Written informed consent by patient or a legally accepted representative
Exclusion Criteria:
- Pregnancy and lactation period (during study treatment)
- Concomitant or previous high-dose therapy with glucocorticoids; previous treatment
with glucocorticoids will be accepted, if it has been low dose (i. e. lower than the
Cushing threshold) and has been stopped at least 3 months before study participation
- Suspected or known hypersensitivity to hydrocortisone or any of its components
- Albumine less than 2,5 g/dl
- Suspected or known drug or alcohol abuse
- Planned treatment for thyroid dysfunction or a planned change in established thyroid
treatment
- Any condition which in the opinion of the investigator makes the patient unsuitable
for inclusion.
- Participation in another clinical trial with investigational new drugs
- Severe medical or psychiatric disease
- Change of dosage of any other drug which might influence the corticotrope axis or
cognitive function (e. g. antidepressive treatment) during the last 3 weeks
- Oral contraceptives
- Severe disturbances in articulation, visual faculty or hearing
- Any elective surgery or medical treatment planned in the observation period
- Intensive Care treatment
Locations and Contacts
Schön Klinik Bad Aibling, Bad Aibling, Bavaria 83043, Germany
Additional Information
Click here for more information about endocrinological diseases
Starting date: February 2010
Last updated: April 7, 2015
|